Page 1

3rd Quarter 2021 Results 3rd Quarter 2021 Sales Worldwide Increased $ 23.3B 10.7 % Diluted Earnings Per Share Increased $ 1.37 3.0 % 085 | Excluding acquisitions / divestitures on an operational basis Worldwide Increased 10.6 % * Adjusted Diluted Earnings Per Share * Increased $ 2.60 | 18.2 % " Our third - quarter results demonstrate solid performance across Johnson & Johnson , driven by robust above - market results in Pharmaceuticals , ongoing recovery in Medical Devices , and strong growth in Consumer Health . In the face of evolving marketplace dynamics resulting from the effects of COVID - 19 and other global trends , we have continued to demonstrate the responsiveness and agility required to meet the needs of our stakeholders , while also successfully investing in a pipeline of innovation and key commercial platforms to drive our future growth . I am incredibly proud of our Company's transformative growth over the last decade . As I prepare to transition the role of CEO to Joaquin Duato in January , I want to extend my deepest gratitude to our colleagues around the globe who work tirelessly to deliver solutions to address the world's most urgent and unmet healthcare challenges . " Alex Gorsky Chairman and Chief Executive Officer Johnson & Johnson $ 3.7 Billion Ô $ 13.0 Billion $ 6.6 Billion $ Worldwide Consumer Health Sales Consumer Health worldwide reported sales increased 5.3 % or 4.1 % operationally¹ . Primary operational drivers : Aveeno . TYLENOL Motrin B ZARBEE'S Imodium NATURALS Stelara ( ustekinumab ) Worldwide Pharmaceutical Sales Pharmaceutical worldwide reported sales increased 13.8 % or 13.2 % operationally¹ . Primary operational drivers : Uptravi selexipag Johnson & Johnson ( daratumumab ) injection for intra 100mm , 400m / 20 DARZALEX Tremfya Erleada ( guselkumab ) ( apalutamide ) 60mg tablets O INVEGA SUSTENNA paliperidone palmitate M Electrophysiology Wound Closure Energy Aveeno . baby Worldwide Medical Devices Sales Medical Devices worldwide reported sales increased 8.0 % or 7.0 % operationally¹ . Primary operational drivers : Biosurgery Opsumit . macitentan Surgical Vision Endocutters 8 Contact Lens Note : values may have been rounded For full financial data and non - GAAP reconciliations , please refer to Johnson & Johnson's earnings release issued on October 19 , 2021 , available at http://www.investor.jnj.com/sales-earnings.cfm . * Non - GAAP financial measure ; non - GAAP financial measures should not be considered replacements for , and should be read together with , the most comparable GAAP financial measures . ¹Non - GAAP measure ; excludes the impact of translational currency . Caution Concerning Forward - Looking Statements : This document contains " forward - looking statements " as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance . You are cautioned not to rely on these forward - looking statements , which are based on current expectations of future events . For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions , expectations , and projections expressed in any forward - looking statements , review the " Note to Investors Concerning Forward - Looking Statements " included in the Johnson & Johnson earnings release issued on October 19 , 2021 , as well as the most recently filed Johnson & Johnson Reports on Forms 10 - K and 10 - Q . Johnson & Johnson does not undertake to update any forward - looking statement as a result of new information or future events or developments .